Pharma News

From the U.S. FDA’s progressive approach to drug labeling to European market pressures confronting legacy drugmakers, the landscape is shifting beneath industry feet.

In a candid address to investors and industry stakeholders, Novo Nordisk’s CEO Mike Doustdar has signaled that the Danish pharmaceutical giant expects notable headwinds within its international operations throughout 2026.

U.S. Food and Drug Administration (FDA) took an action that offered palpable relief to the global weight-loss drug market: it instructed pharmaceutical companies to remove warnings about “suicidal ideation and suicidal behavior” from the labels of certain

With the patent expiry of semaglutide—the active ingredient behind blockbuster drugs like Ozempic and Wegovy—in India, select regulated markets, and emerging economies, a massive revenue opportunity exceeding ₹50,000 crore (approximately $6 billion) has o

Novo Nordisk has officially launched an oral version of its blockbuster drug Wegovy in the United States, offering a needle-free alternative for millions who dread daily injections.

When iFlytek, Alipay, and Baidu each secured government healthcare AI contracts worth over RMB 100 million within a single month, the entire industry seemed to be wheeled out of the ICU and into a VIP recovery suite—breathing easier, pulse stabilizing, ey

Sanofi’s decision to acquire Dynavax Technologies for USD 2.2 billion in an all-cash transaction is far more than a portfolio expansion — it is a signal that the vaccine market is entering a new competitive era shaped by adult immunization, geopolitical s

The global pharmaceutical industry is entering a metabolic revolution. According to industry leaders including Sun Pharma, obesity and metabolic disease therapies are rapidly becoming the most powerful growth engines in global pharma.

Indian Immunologicals Limited has firmly rejected warnings issued by Australian authorities alleging counterfeit rabies vaccine circulation linked to Indian manufacturing.

Minoxidil, one of the most widely used hair-loss treatments in the world, is now under regulatory review following reports of eye disorders and unintended infant exposure linked to household use.

Recent quality testing in India revealed substandard samples among widely used medications for diabetes, hypertension, infections, and allergies.

Lupin has received tentative U.S. FDA approval for its oral multiple-sclerosis treatment, reinforcing its growing footprint in complex generic neurology products.

Vertex Pharmaceuticals announced encouraging new data showing that its gene-editing therapy demonstrated strong efficacy in younger pediatric patients with inherited blood disorders, further expanding the drug’s long-term commercial horizon.

Eli Lilly achieved a major market access milestone after Mounjaro was officially added to China’s national medical insurance list for diabetes treatment, dramatically improving affordability and penetration prospects across the country.

Structure-based drug developer Structure Therapeutics has reported that its experimental oral obesity therapy delivered up to 11% weight loss in a mid-stage clinical study, placing it among the most competitive non-injectable candidates in development.

The global obesity drug race has entered a new competitive phase as Wegovy’s momentum softens following multiple price reductions, while Mounjaro continues to dominate prescription rankings.

In a landmark regulatory first, the U.S. FDA has qualified its first artificial-intelligence tool designed to accelerate liver-disease drug development, validating AI as an official decision-support instrument in pharmaceutical research.

India’s deteriorating air quality has triggered a sharp rise in respiratory medicine consumption, with sales of asthma, COPD, and allergy drugs spiking strongly in November.

The U.S. Food and Drug Administration has launched a fresh safety scrutiny of newly approved RSV therapies for infants, signaling heightened regulatory caution as real-world usage expands.

Zydus Lifesciences has taken a major step into the global oncology biosimilar battlefield after announcing it will commercialize Formycon AG’s biosimilar version of Keytruda in the United States and Canada, marking one of the most strategically important